---
title: "Aptevo net loss widens to $13.1 million in FY26 H1; operating cash outflow narrows to $13.4 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295933270.md"
description: "Aptevo Therapeutics reported a widened net loss of $13.1 million for FY26 H1, with operating cash outflow narrowing to $13.42 million. R&D expenses rose to $7.62 million, driven by the mipletamig program. The company holds $9.8 million in cash, which management states will not sustain operations for at least one year. Additionally, Aptevo continued dose optimization for the RAINIER trial and entered a 50/50 radiopharmaceutical collaboration with Niowave."
datetime: "2026-08-14T12:16:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295933270.md)
  - [en](https://longbridge.com/en/news/295933270.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295933270.md)
generator: "portal-rs"
---

# Aptevo net loss widens to $13.1 million in FY26 H1; operating cash outflow narrows to $13.4 million

-   Aptevo reported a net loss of USD 13.1 million for the six months ended June 30, 2026; operating cash outflow was USD 13.42 million. \* Research and development spending rose to USD 7.62 million; mipletamig program costs increased to USD 3.95 million. \* General and administrative expense was USD 5.7 million; other income increased to USD 0.2 million on higher interest income. \* Cash and cash equivalents totaled USD 9.8 million at June 30, 2026; management said existing cash is not expected to fund operations for at least one year. \* RAINIER trial dose optimization for mipletamig continued; Aptevo also signed a 50⁄50 radiopharmaceutical collaboration with Niowave. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350559), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [Aptevo Therapeutics announces special shareholder meeting](https://longbridge.com/en/news/297564634.md)
- [Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™](https://longbridge.com/en/news/297635298.md)
- [Champions Oncology adds in-house SPECT/CT imaging to radiopharmaceutical development platform](https://longbridge.com/en/news/297657351.md)
- [Luxbright verifies 200W output across 100-200kV range for advanced microfocus X-ray tube](https://longbridge.com/en/news/298003437.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**